A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

Trial Profile

A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism; Venous thrombosis
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Nov 2016 Planned number of patients changed from 48 to 60.
    • 18 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top